Biogen: all 548 studies
Page 6 of 6. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- GER-009-06-AVX Early Therapy in Multiple SclerosisCompletedNCT00492570
- Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing AntibodiesCompletedNCT00492466Phase 4
- GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy VolunteersCompletedNCT00488566Phase 1
- TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of WorldCompletedNCT00483847
- TYSABRI Global Observational Program in SafetyCompletedNCT00477113
- Pregnancy Exposure Registry for Tysabri®CompletedNCT00472992
- Evaluation of Natalizumab for thE Relief of MS Associated FatiGueCompletedNCT00464074
- BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid ArthritisTerminatedNCT00458861Phase 2
- BIIB014 Phase 2a MonotherapyWithdrawnNCT00451815Phase 2
- Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's DiseaseCompletedNCT00442780Phase 2
- Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's DiseaseCompletedNCT00438607Phase 2
- A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)CompletedNCT00424788Early Phase 1
- CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD StudyCompletedNCT00412412Phase 1
- Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00391066Phase 2
- Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00384150Phase 3
- A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00363636Phase 3
- Study of Oral CNF2024 (BIIB021) in Advanced Solid TumorsCompletedNCT00345189Phase 1
- Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLLTerminatedNCT00344786Phase 1
- Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLLTerminatedNCT00319930Phase 1
- Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid ArthritisCompletedNCT00292422Phase 2
- A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple SclerosisCompletedNCT00288990
- Open Label Natalizumab Safety Extension Study for Subjects With Crohn's DiseaseCompletedNCT00280956Phase 4
- Open-Label Natalizumab Safety Extension StudyCompletedNCT00276172Phase 3
- Safety and Tolerability of Repeat Courses of IM AlefaceptCompletedNCT00233662Phase 3
- Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MSCompletedNCT00168766Phase 4
- Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)CompletedNCT00168740Phase 3
- Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's LymphomaCompletedNCT00168727Phase 4
- Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)CompletedNCT00168714
- Efficacy and Safety of BG00012 in MSCompletedNCT00168701Phase 2
- AVONEX® Combination Trial - "ACT"CompletedNCT00112034Phase 4
- Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver MetastasesCompletedNCT00107861Phase 1/2
- Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid TumorsTerminatedNCT00105170Phase 1
- Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT00103558Phase 1/2
- Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal AdenocarcinomaTerminatedNCT00102024Phase 1/2
- Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT00099489Phase 2
- Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00097760Phase 2
- Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00090038Phase 4
- A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's DiseaseCompletedNCT00078611Phase 3
- Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's LymphomaTerminatedNCT00057343Phase 3
- Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's DiseaseCompletedNCT00055536Phase 2
- Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's DiseaseCompletedNCT00055367Phase 2
- Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00048555Phase 1/2
- Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)CompletedNCT00046488Phase 1
- Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCompletedNCT00032799Phase 3
- Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCompletedNCT00032786Phase 3
- Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV GliomasCompletedNCT00031083Phase 1
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisCompletedNCT00030966Phase 3
- Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisCompletedNCT00027300Phase 3